{"id":90176,"date":"2016-11-30T12:43:32","date_gmt":"2016-11-30T12:43:32","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=90176"},"modified":"2016-11-30T12:43:32","modified_gmt":"2016-11-30T12:43:32","slug":"global-diabetes-obesity-drug-development-pipeline-review-2016-cluster-is-dominated-by-therapeutics-indicated-for-t1dm-and-t2dm-hexa-reports","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-diabetes-obesity-drug-development-pipeline-review-2016-cluster-is-dominated-by-therapeutics-indicated-for-t1dm-and-t2dm-hexa-reports_90176.html","title":{"rendered":"Global Diabetes & Obesity Drug Development Pipeline Review 2016: Cluster is Dominated by Therapeutics Indicated for T1DM and T2DM – Hexa Reports"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Get key Market Research Reports and Insightful Company Profiles”<\/div>\n<\/div>\n<\/div>\n
An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues<\/div>\n

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.<\/p>\n

The combined therapy area of diabetes and obesity presents a strong pipeline, accounting for a large proportion of the overall metabolic disorders therapy area. The majority of products are small molecules and biologics, which reflects the overall pharmacotherapeutic market trend.<\/p>\n

An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products for obesity is dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM pipeline will continue to grow with the rising obesity incidence.<\/p>\n

Browse Detail Report With TOC @ <\/strong>http:\/\/www.hexareports.com\/report\/diabetes-and-obesity-drug-development-pipeline-review-2016\/details<\/a><\/p>\n

Scope<\/strong><\/p>\n

– Which companies are the most active within the pipeline for diabetes and obesity?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?
– What are the most important R&D milestones and data publications to have occurred in this disease area?
– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.
– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these.
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.<\/p>\n

Request A Sample copy of This Report @ <\/strong>http:\/\/www.hexareports.com\/sample\/169581<\/a><\/p>\n

Table of Contents<\/strong><\/p>\n

Table of Contents 4
List of Tables 6
List of Figures 22
Diabetes and Obesity Report Coverage 24
Type 1 Diabetes (Juvenile Diabetes) Overview 24
Type 2 Diabetes Overview 24
Obesity Overview 24
Therapeutics Development by Stage 25
Type 1 diabetes (Juvenile Diabetes) 25
Type 2 Diabetes 27
Obesity 29
Therapeutics under Development by Companies 31
Type 1 Diabetes (Juvenile Diabetes) 31
Type 2 Diabetes 41
Obesity 61
Therapeutics under Investigation by Universities\/Institutes 70
Type 1 diabetes (Juvenile Diabetes) 70
Type 2 Diabetes 72
Obesity 75
Pipeline Products Glance 78
Type 1 diabetes (Juvenile Diabetes) 78
Type 2 Diabetes 81
Obesity 84
Products under Development by Companies 87
Type 1 diabetes (Juvenile Diabetes) 87
Type 2 Diabetes 98
Obesity 121
Products under Investigation by Universities\/Institutes 130
Type 1 diabetes (Juvenile Diabetes) 130
Type 2 Diabetes 133
Obesity 139
Companies Involved in Therapeutics Development 143
Type 1 diabetes (Juvenile Diabetes) 143
Type 2 Diabetes 196
Obesity 309
Therapeutics Assessment 361<\/p>\n

Related Reports:<\/p>\n

Cat Allergy – Pipeline Review, H2 2016:
http:\/\/www.hexareports.com\/report\/cat-allergy-pipeline-review-h2-2016\/details<\/a><\/p>\n

Restenosis – Pipeline Review, H2 2016:
http:\/\/www.hexareports.com\/report\/restenosis-pipeline-review-h2-2016\/details<\/a><\/p>\n

About Us:<\/strong><\/p>\n

Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Hexa Reports
Contact Person:<\/strong> Ryan Shaw
Email:<\/strong> sales@hexareports.com
Phone:<\/strong> 1-800-489-3075
Address:<\/strong>Felton Office Plaza, 6265 Highway 9
City:<\/strong> Felton
State:<\/strong> California
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.hexareports.com\/report\/diabetes-and-obesity-drug-development-pipeline-review-2016\/details<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Get key Market Research Reports and Insightful Company Profiles” An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues The diabetes and obesity disease cluster is … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-90176","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/90176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=90176"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/90176\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=90176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=90176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=90176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}